Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06865040

Acronym

TICTAC

Enrollment

266

Registered

2025-03-07

Start date

2025-07-31

Completion date

2028-09-01

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pulmonary Complications (PPCs), Thoracic Surgery

Keywords

Thoracic surgery, postoperative pulmonary complications, Inhaled therapy, bronchodilators, B2 mimetics

Brief summary

The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications

Interventions

DRUGFormoterol Fumarate 12 mcg (Foradil Aerolizer)

Administration in the interventional arm of long-acting inhaled ß-2 mimetics: FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7.

OTHERUsual treatment

usual treatment

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult (\>18 years) * Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route * Naïve to long-term inhaled bronchodilator therapy * High risk of post-operative pulmonary complications (Pre-operative FEV1 \< 80%)

Exclusion criteria

* Patient refusal * Pregnancy * Emergency surgery * Patient with a physiological status of WHO IV or ASA ≥ IV * Asthma * Patients treated with long-acting bronchodilators * Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \< 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \< 3 months * High-grade unresponsive conductive disorders or unstable arrhythmia * Thyrotoxicosis, pheochromocytoma * Unbalanced diabetes * Hypersensitivity to ß-2 mimetics or lactose * Current participation in a trial of another drug therapy

Design outcomes

Primary

Measure	Time frame	Description
Number of postoperative pulmonary complication	day 7	Number of postoperative pulmonary complications (PPC) at day 7 after a thoracic surgery for lung resection

Countries

France

Contacts

CONTACTTHOMAS LEFEBVRE, MD

Lefebvre.Thomas@chu-amiens.fr33 + 322087889

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026